

# Vivian A Fonseca

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4014850/vivian-a-fonseca-publications-by-citations.pdf>

**Version:** 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210  
papers

12,613  
citations

56  
h-index

109  
g-index

232  
ext. papers

14,314  
ext. citations

7.5  
avg, IF

6.55  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 210 | Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 2227-36                              | 27.4 | 587       |
| 209 | AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. <i>Endocrine Practice</i> , <b>2017</b> , 23, 1-87                               | 3.2  | 535       |
| 208 | Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. <i>Diabetes Care</i> , <b>2004</b> , 27, 256-63   | 14.6 | 479       |
| 207 | Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , <b>2007</b> , 30, 162-72                            | 14.6 | 405       |
| 206 | Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 283, 1695-702                                  | 27.4 | 405       |
| 205 | Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>Diabetes Care</i> , <b>2010</b> , 33, 1578-84   | 14.6 | 342       |
| 204 | CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , <b>2016</b> , 22, 84-113   | 3.2  | 333       |
| 203 | CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , <b>2018</b> , 24, 91-120  | 3.2  | 321       |
| 202 | Defining and characterizing the progression of type 2 diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32 Suppl 2, S151-6  | 14.6 | 317       |
| 201 | Nonhypoglycemic effects of thiazolidinediones. <i>Annals of Internal Medicine</i> , <b>2001</b> , 134, 61-71   | 8    | 304       |
| 200 | CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , <b>2017</b> , 23, 207-238 | 3.2  | 302       |
| 199 | Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. <i>Diabetes Care</i> , <b>2003</b> , 26, 1485-9  | 14.6 | 299       |
| 198 | Hypoglycemia, diabetes, and cardiovascular events. <i>Diabetes Care</i> , <b>2010</b> , 33, 1389-94  | 14.6 | 296       |
| 197 | The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2010</b> , 152, 346-57  | 8    | 287       |
| 196 | Systematic review: glucose control and cardiovascular disease in type 2 diabetes. <i>Annals of Internal Medicine</i> , <b>2009</b> , 151, 394-403  | 8    | 249       |
| 195 | The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. <i>Diabetes Care</i> , <b>2010</b> , 33, 1516-22                               | 14.6 | 242       |
| 194 | Effect of thiazolidinediones on body weight in patients with diabetes mellitus. <i>American Journal of Medicine</i> , <b>2003</b> , 115 Suppl 8A, 42S-48S  | 2.4  | 228       |

|     |  |      |     |
|-----|--|------|-----|
| 193 | Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. <i>Kidney International</i> , <b>2009</b> , 75, 1272-1277   | 9.9  | 227 |
| 192 | Oxidants in chronic kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 16-28   | 12.7 | 220 |
| 191 | Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. <i>Diabetes Care</i> , <b>2008</b> , 31, 1479-84   | 14.6 | 215 |
| 190 | Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. <i>Diabetes Care</i> , <b>2009</b> , 32 Suppl 2, S237-45  | 14.6 | 211 |
| 189 | Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 1336-9  | 14.6 | 207 |
| 188 | CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , <b>2019</b> , 25, 69-100  | 3.2  | 191 |
| 187 | Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). <i>Diabetes Care</i> , <b>2012</b> , 35, 1225-31   | 14.6 | 183 |
| 186 | Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2013</b> , 159, 1-12  | 8    | 177 |
| 185 | Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. <i>Diabetes Care</i> , <b>2014</b> , 37, 2317-25                                      | 14.6 | 173 |
| 184 | Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. <i>Archives of Internal Medicine</i> , <b>2008</b> , 168, 1531-40  |      | 169 |
| 183 | Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. <i>Endocrine Reviews</i> , <b>2017</b> , 38, 173-188   | 27.2 | 144 |
| 182 | Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. <i>Metabolism: Clinical and Experimental</i> , <b>1996</b> , 45, 133-5  | 12.7 | 126 |
| 181 | Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). <i>Annals of Epidemiology</i> , <b>2004</b> , 14, 686-95 | 6.4  | 116 |
| 180 | Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. <i>Diabetes Care</i> , <b>2009</b> , 32, 1632-8  | 14.6 | 115 |
| 179 | Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. <i>Metabolism: Clinical and Experimental</i> , <b>1998</b> , 47, 686-9   | 12.7 | 109 |
| 178 | Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 384-92  | 6.7  | 106 |
| 177 | Effects of beta-blockers on glucose and lipid metabolism. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 615-29   | 2.5  | 101 |
| 176 | Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>1998</b> , 12, 181-6  | 3.2  | 98  |

|     |  |      |    |
|-----|--|------|----|
| 175 | Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. <i>Lancet, The</i> , <b>2012</b> , 379, 2262-9                                    | 40   | 91 |
| 174 | Therapeutic approaches to target inflammation in type 2 diabetes. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 162-7  | 5.5  | 90 |
| 173 | Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. <i>Diabetes Care</i> , <b>2012</b> , 35, 1126-32  | 14.6 | 86 |
| 172 | Diabetic nephropathy and retinopathy. <i>Medical Clinics of North America</i> , <b>2004</b> , 88, 1001-36, xi  | 7    | 84 |
| 171 | Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. <i>Endocrine Reviews</i> , <b>1999</b> , 20, 738-59  | 27.2 | 83 |
| 170 | Drugs affecting homocysteine metabolism: impact on cardiovascular risk. <i>Drugs</i> , <b>2002</b> , 62, 605-16  | 12.1 | 79 |
| 169 | MON-160 Effect Of The Combination Conjugated Estrogens And Bazedoxifene On Glucose Homeostasis In Obese Postmenopausal Women: A Placebo-controlled Randomized Pilot Trial. <i>Journal of the Endocrine Society</i> , <b>2019</b> , 3,                        | 0.4  | 78 |
| 168 | Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , <b>2003</b> , 19, 635-41   | 2.5  | 75 |
| 167 | Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. <i>Diabetes Care</i> , <b>2010</b> , 33, 730-2                            | 14.6 | 74 |
| 166 | Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37, 2934-9   | 14.6 | 72 |
| 165 | Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. <i>Metabolism: Clinical and Experimental</i> , <b>2000</b> , 49, 736-41   | 12.7 | 71 |
| 164 | Body weight changes with beta-blocker use: results from GEMINI. <i>American Journal of Medicine</i> , <b>2007</b> , 120, 610-5   | 2.4  | 70 |
| 163 | Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. <i>American Journal of Medicine</i> , <b>2005</b> , 118, 939-47   | 2.4  | 70 |
| 162 | Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>2013</b> , 27, 268-73 | 3.2  | 68 |
| 161 | Surge in newly identified diabetes among medicaid patients in 2014 within medicaid expansion States under the affordable care act. <i>Diabetes Care</i> , <b>2015</b> , 38, 833-7  | 14.6 | 67 |
| 160 | Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 13M-18M  | 3    | 67 |
| 159 | Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. <i>Journal of Diabetes and Its Complications</i> , <b>2014</b> , 28, 399-405       | 3.2  | 61 |
| 158 | From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 146-56  | 3.2  | 60 |

|     |  |      |    |
|-----|--|------|----|
| 157 | Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus. <i>American Journal of Nephrology</i> , <b>2019</b> , 49, 331-342  | 4.6  | 59 |
| 156 | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1579-86            | 14.6 | 59 |
| 155 | Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 1343-52  | 6.9  | 59 |
| 154 | Type 2 Diabetes and Hypertension. <i>Circulation Research</i> , <b>2019</b> , 124, 930-937   | 15.7 | 56 |
| 153 | Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 141-9   | 2.4  | 55 |
| 152 | Bile acid sequestrants for lipid and glucose control. <i>Current Diabetes Reports</i> , <b>2010</b> , 10, 70-7   | 5.6  | 54 |
| 151 | The metabolic syndrome, hyperlipidemia, and insulin resistance. <i>Clinical Cornerstone</i> , <b>2005</b> , 7, 61-72   |      | 54 |
| 150 | A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. <i>American Journal of the Medical Sciences</i> , <b>2004</b> , 328, 274-80 | 2.2  | 53 |
| 149 | Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , <b>2018</b> , 138, 2908-2918   | 16.7 | 48 |
| 148 | Association between Inflammation and Biological Variation in Hemoglobin A1c in U.S. Nondiabetic Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 2364-71   | 5.6  | 45 |
| 147 | Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. <i>Current Diabetes Reports</i> , <b>2003</b> , 3, 248-54   | 5.6  | 45 |
| 146 | Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. <i>BMJ Open</i> , <b>2019</b> , 9, e024954   | 3    | 45 |
| 145 | Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2013</b> , 27, 177-83  | 3.2  | 44 |
| 144 | Overview of metformin: special focus on metformin extended release. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 1797-805  | 4    | 43 |
| 143 | Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. <i>Diabetes Care</i> , <b>2013</b> , 36, 2162-8  | 14.6 | 42 |
| 142 | GLP-1 Receptor in Pancreatic ECells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. <i>Diabetes</i> , <b>2019</b> , 68, 34-44  | 0.9  | 39 |
| 141 | Racial disparity of eye examinations among the U.S. working-age population with diabetes: 2002-2009. <i>Diabetes Care</i> , <b>2014</b> , 37, 1321-8   | 14.6 | 38 |
| 140 | Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1125-1134  | 4.4  | 37 |

|     |   |      |    |
|-----|---|------|----|
| 139 | Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. <i>Metabolism: Clinical and Experimental</i> , <b>2005</b> , 54, 645-52  | 12.7 | 37 |
| 138 | Benefits of timely basal insulin control in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 295-301   | 3.2  | 35 |
| 137 | Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. <i>Nature Reviews Drug Discovery</i> , <b>2009</b> , 8, 361-7  | 64.1 | 34 |
| 136 | Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. <i>Diabetes Care</i> , <b>2003</b> , 26, 1685-90  | 14.6 | 33 |
| 135 | The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. <i>Metabolism: Clinical and Experimental</i> , <b>2002</b> , 51, 783-6  | 12.7 | 33 |
| 134 | Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. <i>Clinical Cornerstone</i> , <b>2007</b> , 8 Suppl 7, S7-18  |      | 32 |
| 133 | Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2003</b> , 8, 297-305  | 2.6  | 32 |
| 132 | Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. <i>Endocrine Practice</i> , <b>2010</b> , 16, 629-40   | 3.2  | 30 |
| 131 | Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. <i>Journal of Diabetes and Its Complications</i> , <b>2014</b> , 28, 742-9 | 3.2  | 29 |
| 130 | Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126704  | 3.7  | 28 |
| 129 | PAX4 Gene Transfer Induces $\beta$ -Cell Phenotypic Conversion and Confers Therapeutic Benefits for Diabetes Treatment. <i>Molecular Therapy</i> , <b>2016</b> , 24, 251-260  | 11.7 | 27 |
| 128 | Saxagliptin overview: special focus on safety and adverse effects. <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 103-9   | 4.1  | 27 |
| 127 | Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. <i>Cardiology Clinics</i> , <b>2008</b> , 26, 639-48  | 2.5  | 27 |
| 126 | Insulin resistance syndrome: options for treatment. <i>Southern Medical Journal</i> , <b>1999</b> , 92, 2-15  | 0.6  | 27 |
| 125 | Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. <i>Vascular Pharmacology</i> , <b>2006</b> , 45, 29-35   | 5.9  | 26 |
| 124 | Mechanisms and therapeutic targets in type 2 diabetes mellitus. <i>Drug Discovery Today Disease Mechanisms</i> , <b>2004</b> , 1, 151-157   |      | 26 |
| 123 | Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. <i>Current Medical Research and Opinion</i> , <b>2003</b> , 19, 609-13   | 2.5  | 26 |
| 122 | The Hurricane Katrina aftermath and its impact on diabetes care: observations from "ground zero": lessons in disaster preparedness of people with diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 158-60   | 14.6 | 26 |

|     |   |      |    |
|-----|---|------|----|
| 121 | Economic burden of hypoglycemia in patients with Type 2 diabetes. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2012</b> , 12, 47-51   | 2.2  | 25 |
| 120 | Differential association of birth weight with cardiovascular risk variables in African-Americans and Whites: the Bogalusa heart study. <i>Annals of Epidemiology</i> , <b>2004</b> , 14, 258-64                                 | 6.4  | 25 |
| 119 | Weight Loss in Underserved Patients - A Cluster-Randomized Trial. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 909-918   | 59.2 | 25 |
| 118 | Identification and treatment of prediabetes to prevent progression to type 2 diabetes. <i>Clinical Cornerstone</i> , <b>2007</b> , 8, 10-8; discussion 19-20  |      | 24 |
| 117 | Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. <i>American Journal of Medicine</i> , <b>2007</b> , 120, S18-25  | 2.4  | 24 |
| 116 | New developments in diabetes management: medications of the 21st century. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 477-84   | 3.5  | 22 |
| 115 | GLYCATED ALBUMIN AT 4 WEEKS CORRELATES WITH A1C LEVELS AT 12 WEEKS AND REFLECTS SHORT-TERM GLUCOSE FLUCTUATIONS. <i>Endocrine Practice</i> , <b>2015</b> , 21, 1195-203   | 3.2  | 22 |
| 114 | Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 52B-8B                                     | 3    | 22 |
| 113 | The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , <b>2006</b> , 5, 273-86 |      | 22 |
| 112 | Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease. <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 713-20; quiz 721-2                    | 2.3  | 22 |
| 111 | Effects of the thiazolidinediones on cardiovascular risk factors. <i>American Journal of Cardiovascular Drugs</i> , <b>2002</b> , 2, 149-56   | 4    | 22 |
| 110 | Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. <i>Journal of Diabetes and Its Complications</i> , <b>2006</b> , 20, 14-20   | 3.2  | 21 |
| 109 | Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 1621-8                        | 2.5  | 20 |
| 108 | Baseline Vitamin D Status, Sleep Patterns, and the Risk of Incident Type 2 Diabetes in Data From the UK Biobank Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 2776-2784   | 14.6 | 19 |
| 107 | Management of type 2 diabetes: oral agents, insulin, and injectables. <i>Journal of the American Dietetic Association</i> , <b>2008</b> , 108, S29-33   |      | 17 |
| 106 | Identification and treatment of prediabetes to prevent progression to type 2 diabetes. <i>Clinical Cornerstone</i> , <b>2008</b> , 9, 51-9; discussion 60-1   |      | 17 |
| 105 | Commentary: the PROactive study--the glass is half full. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 25-7   | 5.6  | 17 |
| 104 | Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> ,                                | 5.6  | 16 |

|     |   |      |    |
|-----|---|------|----|
| 103 | The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. <i>Journal of Diabetes and Its Complications</i> , <b>2014</b> , 28, 874-9  | 3.2  | 16 |
| 102 | Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>2011</b> , 25, 143-50                    | 3.2  | 16 |
| 101 | Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. <i>Journal of Diabetes and Its Complications</i> , <b>2008</b> , 22, 303-8     | 3.2  | 16 |
| 100 | The impact of antidiabetic therapies on cardiovascular disease. <i>Current Atherosclerosis Reports</i> , <b>2005</b> , 7, 50-7  | 6    | 16 |
| 99  | BMI is Associated with Coronavirus Disease 2019 Intensive Care Unit Admission in African Americans. <i>Obesity</i> , <b>2020</b> , 28, 1798-1801  | 8    | 16 |
| 98  | Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. <i>American Journal of Medicine</i> , <b>2011</b> , 124, S54-61 | 2.4  | 15 |
| 97  | The role of basal insulin therapy in patients with type 2 diabetes mellitus. <i>Insulin</i> , <b>2006</b> , 1, 51-60  |      | 15 |
| 96  | Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. <i>Endocrine Practice</i> , <b>2000</b> , 6, 435-41   | 3.2  | 15 |
| 95  | Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. <i>Pharmacoeconomics</i> , <b>2019</b> , 37, 921-929                     | 4.4  | 15 |
| 94  | Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 465-473   | 6.9  | 15 |
| 93  | The American Diabetes Association diabetes research perspective. <i>Diabetes Care</i> , <b>2012</b> , 35, 1380-7  | 14.6 | 14 |
| 92  | Sex Differences in Cardiovascular Risk Profile From Childhood to Midlife Between Individuals Who Did and Did Not Develop Diabetes at Follow-up: The Bogalusa Heart Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 635-643        | 14.6 | 13 |
| 91  | Time to recovery in diabetes and comorbidities following Hurricane Katrina. <i>Disaster Medicine and Public Health Preparedness</i> , <b>2010</b> , 4 Suppl 1, S33-8  | 2.8  | 13 |
| 90  | Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. <i>Cardiology Clinics</i> , <b>2005</b> , 23, 119-38                                      | 2.5  | 13 |
| 89  | Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells. <i>American Journal of Physiology - Renal Physiology</i> , <b>2020</b> , 318, F67-F75    | 4.3  | 13 |
| 88  | Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,   | 5.6  | 13 |
| 87  | Management of the insulin resistance syndrome. <i>Current Diabetes Reports</i> , <b>2001</b> , 1, 140-7   | 5.6  | 12 |
| 86  | Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. <i>Diabetes Care</i> , <b>2021</b> , 44, 164-173   | 14.6 | 12 |



|    |   |      |    |
|----|---|------|----|
| 85 | Biomedical Journals and Preprint Services: Friends or Foes?. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 453-458  | 5.5  | 11 |
| 84 | Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 1206-15   | 3.5  | 11 |
| 83 | Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). <i>Diabetes Research and Clinical Practice</i> , <b>2018</b> , 140, 45-54  | 7.4  | 11 |
| 82 | Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 305-10  | 4.1  | 11 |
| 81 | The American Diabetes Association diabetes research perspective. <i>Diabetes</i> , <b>2012</b> , 61, 1338-45  | 0.9  | 11 |
| 80 | Cardiovascular events and insulin therapy: a retrospective cohort analysis. <i>Diabetes Research and Clinical Practice</i> , <b>2008</b> , 81, 97-104   | 7.4  | 11 |
| 79 | Economic burden of hypoglycemia: Utilization of emergency department and outpatient services in the United States (2005-2009). <i>Journal of Medical Economics</i> , <b>2016</b> , 19, 852-7  | 2.4  | 11 |
| 78 | Update on Safety Issues Related to Antihyperglycemic Therapy. <i>Diabetes Spectrum</i> , <b>2014</b> , 27, 92-100   | 1.9  | 10 |
| 77 | Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. <i>Molecular and Cellular Biochemistry</i> , <b>2009</b> , 330, 1-8                    | 4.2  | 10 |
| 76 | Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. <i>Metabolic Syndrome and Related Disorders</i> , <b>2006</b> , 4, 179-84   | 2.6  | 10 |
| 75 | Potential cardiovascular benefits of insulin sensitizers. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2005</b> , 34, 117-35   | 5.5  | 10 |
| 74 | Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment. <i>Nature Reviews Endocrinology</i> , <b>2014</b> , 10, 276-81   | 15.2 | 9  |
| 73 | Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors. <i>Scientific Reports</i> , <b>2017</b> , 7, 7964   | 4.9  | 9  |
| 72 | The effects of insulin on the endothelium. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2007</b> , 36 Suppl 2, 20-6  | 5.5  | 9  |
| 71 | Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 995-1005 | 3.6  | 7  |
| 70 | Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL): Rationale, design and baseline characteristics. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 67, 1-10  | 2.3  | 7  |
| 69 | Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2931-2941   | 5.6  | 6  |
| 68 | A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. <i>Current Diabetes Reports</i> , <b>2020</b> , 20, 12  | 5.6  | 6  |

|    |  |      |   |
|----|--|------|---|
| 67 | Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. <i>Value in Health</i> , <b>2019</b> , 22, 1402-1409  | 3.3  | 6 |
| 66 | Urinary catalytic iron in obesity. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 272-8   | 5.5  | 6 |
| 65 | Chelation therapy to prevent diabetes-associated cardiovascular events. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2018</b> , 25, 258-266  | 4    | 6 |
| 64 | Using the RE-AIM framework to evaluate internal and external validity of mobile phone-based interventions in diabetes self-management education and support. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2020</b> , 27, 946-956 | 8.6  | 5 |
| 63 | Will the Affordable Care Act (ACA) Improve Racial/Ethnic Disparity of Eye Examination Among US Working-Age Population with Diabetes?. <i>Current Diabetes Reports</i> , <b>2016</b> , 16, 58   | 5.6  | 5 |
| 62 | Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. <i>Pharmacology Research and Perspectives</i> , <b>2020</b> , 8, e00637   | 3.1  | 5 |
| 61 | Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors: A Cluster-Randomized Trial. <i>Circulation</i> , <b>2021</b> , 143, 1202-1214   | 16.7 | 5 |
| 60 | REVISITING THE USE OF PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES. <i>Endocrine Practice</i> , <b>2016</b> , 22, 1343-1346  | 3.2  | 5 |
| 59 | Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 134-41   | 3.2  | 4 |
| 58 | Diabetes INSIDE: Improving Population HbA Testing and Targets in Primary Care With a Quality Initiative. <i>Diabetes Care</i> , <b>2020</b> , 43, 329-336  | 14.6 | 4 |
| 57 | Utility of existing diabetes risk prediction tools for young black and white adults: Evidence from the Bogalusa Heart Study. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 86-93  | 3.2  | 4 |
| 56 | Glucose control and cardiovascular outcomes in individuals with diabetes mellitus: lessons learned from the megatrials. <i>Heart Failure Clinics</i> , <b>2012</b> , 8, 513-22   | 3.3  | 4 |
| 55 | Diabetes mellitus in the next decade: novel pipeline medications to treat hyperglycemia. <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 714-23   | 3.5  | 4 |
| 54 | Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 341-4  | 5.5  | 4 |
| 53 | The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: lessons for managing clinical trials during and after a natural disaster. <i>Contemporary Clinical Trials</i> , <b>2008</b> , 29, 756-61                           | 2.3  | 4 |
| 52 | Diagnosis and treatment of hyperhomocysteinemia. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 54-63   | 6    | 4 |
| 51 | Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2295-2304   | 6.7  | 4 |
| 50 | Diabetes control in Asian Americans - Disparities and the role of acculturation. <i>Primary Care Diabetes</i> , <b>2021</b> , 15, 187-190  | 2.4  | 4 |

|    |   |      |   |
|----|---|------|---|
| 49 | Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors. <i>Diabetes Care</i> , <b>2020</b> , 43, 1530-1536  | 14.6 | 3 |
| 48 | Differential sex effects of systolic blood pressure and low-density lipoprotein cholesterol on type 2 diabetes: Life course data from the Bogalusa Heart Study. <i>Journal of Diabetes</i> , <b>2018</b> , 10, 449-457  | 3.8  | 3 |
| 47 | Variabilities in Childhood Cardiovascular Risk Factors and Incident Diabetes in Adulthood: The Bogalusa Heart Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 1816-1823   | 14.6 | 3 |
| 46 | Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone. <i>Evidence-Based Medicine</i> , <b>2010</b> , 15, 115-6  |      | 3 |
| 45 | Demystifying incretin therapy for type 2 diabetes. Introduction. <i>American Journal of Medicine</i> , <b>2009</b> , 122, S1-2  | 2.4  | 3 |
| 44 | Metabolic syndrome and heart failure. <i>Heart Failure Clinics</i> , <b>2006</b> , 2, 1-11  | 3.3  | 3 |
| 43 | Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. <i>Metabolic Syndrome and Related Disorders</i> , <b>2005</b> , 3, 147-73   | 2.6  | 3 |
| 42 | Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 2847-2852   | 14.6 | 3 |
| 41 | Replacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes. <i>Diabetes Care</i> , <b>2021</b> ,   | 14.6 | 3 |
| 40 | Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women. <i>Diabetes Care</i> , <b>2021</b> , 44, 2564-2572   | 14.6 | 3 |
| 39 | Effects of thiazolidinediones on cardiovascular risk factors. <i>Comprehensive Therapy</i> , <b>2002</b> , 28, 200-6  |      | 2 |
| 38 | DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 36, 108101  | 3.2  | 2 |
| 37 | Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting $\beta$ Cell Survival and $\beta$ Cell Transdifferentiation. <i>Cell Transplantation</i> , <b>2020</b> , 29, 963689720958655  | 4    | 2 |
| 36 | Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107916  | 3.2  | 2 |
| 35 | Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e227705  | 10.4 | 2 |
| 34 | Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial". <i>Circulation</i> , <b>2019</b> , 139, e1017-e1018 | 16.7 | 1 |
| 33 | Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> 2019;42:2298-2306. <i>Diabetes Care</i> , <b>2020</b> , 43, e25                            | 14.6 | 1 |
| 32 | What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. <i>Current Diabetes Reports</i> , <b>2016</b> , 16, 94  | 5.6  | 1 |

|    |   |      |   |
|----|---|------|---|
| 31 | Effects of Linagliptin on Pancreatic Cells of Type 1 Diabetic Mice. <i>Journal of the Endocrine Society</i> , <b>2017</b> , 1, 1224-1234  | 0.4  | 1 |
| 30 | Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2009</b> , 6, 475-487                    |      | 1 |
| 29 | Commentary: Of HOPEs and DREAMs: the quest to prevent type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 4762-3   | 5.6  | 1 |
| 28 | KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease.. <i>Kidney International</i> , <b>2021</b> ,   | 9.9  | 1 |
| 27 | Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women.. <i>Atherosclerosis</i> , <b>2022</b> , 344, 13-19                     | 3.1  | 1 |
| 26 | 174-LB: Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications. <i>Diabetes</i> , <b>2019</b> , 68, 174-LB   | 0.9  | 1 |
| 25 | The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvaa193   | 0.4  | 1 |
| 24 | Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary. <i>Clinical Diabetes</i> , <b>2021</b> , 39, 141-145         | 2.9  | 1 |
| 23 | Sex differences in soluble prorenin receptor in patients with type 2 diabetes. <i>Biology of Sex Differences</i> , <b>2021</b> , 12, 33   | 9.3  | 1 |
| 22 | Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107978  | 3.2  | 1 |
| 21 | Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes.. <i>Diabetes Care</i> , <b>2022</b> , 45, e32-e33 <sup>14.6</sup> |      | 0 |
| 20 | Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.. <i>Journal of Diabetes and Its Complications</i> , <b>2022</b> , 108132  | 3.2  | 0 |
| 19 | Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 961-969  | 1.9  | 0 |
| 18 | Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia. <i>Advances in Therapy</i> , <b>2021</b> , 38, 5238-5252  | 4.1  | 0 |
| 17 | Post-ACA Racial Disparity of Eye Examinations Among the U.S. Noninstitutionalized Population With Diabetes: 2014-2015. <i>Diabetes Care</i> , <b>2019</b> , 42, e70-e72   | 14.6 |   |
| 16 | Exploring the spectrum of incretin therapies: the potential for optimizing patient outcomes. Introduction. <i>American Journal of Medicine</i> , <b>2011</b> , 124, S1-2  | 2.4  |   |
| 15 | Demystifying incretin therapy for type 2 diabetes. Introduction. <i>European Journal of Internal Medicine</i> , <b>2009</b> , 20 Suppl 2, S301-2  | 3.9  |   |
| 14 | DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2007</b> , 2, 567-572   | 4.1  |   |

- 13 Pharmacological treatment of the insulin resistance syndrome in people without diabetes. *Metabolic Syndrome and Related Disorders*, **2005**, 3, 332-8 2.6
- 12 Effects of low-dose candesartan on the rate of re-endothelialisation following vascular wound healing. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2001**, 2, S81-S83 3
- 11 Pioglitazone. *Drugs*, **2000**, 60, 344-345 12.1
- 10 Screening Patients with Prediabetes and Diabetes for Cardiovascular Disease **2021**, 161-173
- 9 Insulin Sensitizers and Cardiovascular Disease **2009**, 81-95
- 8 Pharmacological Treatment of the Insulin Resistance Syndrome in People Without Diabetes. *Metabolic Syndrome and Related Disorders*, **2005**, 3, 260-266 2.6
- 7 Metabolic Syndrome and Type 2 Diabetes Mellitus **2006**, 41-78
- 6 Insulin Resistance Syndrome and Its Vascular Complications **2007**, 375-393
- 5 Intensive Treatment and Complications of Diabetes **2008**, 51-68
- 4 Complications of diabetes **2009**, 41-57
- 3 Inpatient management and post-discharge outcomes of hyperkalemia. *Hospital Practice (1995)*, **2021**, 49, 273-279 2.2
- 2 The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018. *Current Medical Research and Opinion*, **2021**, 37, 1875-1880 2.5
- 1 Changes in body size phenotypes from childhood to adulthood and the associated cardiometabolic outcomes.. *Diabetes Research and Clinical Practice*, **2022**, 187, 109884 7.4